Regarding the metastatic disease, a threshold of PD-L1 expression CPS≥10 has been established for the usage of ICIs, as dictated by KEYNOTE-355 where a statistically significant result in terms of OS with the addition of pembrolizumab was depicted for patients with CPS≥10 (HR: .73, 95%CI: .55–.95, p-value:0.0093) but not for the patients with CPS≥1 (HR:0.86, 95%CI:0.72–1.04, p-value:0.0563) (Cortes et al., 2020b). This evidence concerns the gene CD274 and metastatic neoplasm.